Oral Anaerobutyricum soehngenii augments glycemic control in type 2 diabetes.

This randomized, double-blind, placebo-controlled trial investigated the impact of 14-day Anaerobutyricum soehngenii L2-7 supplementation on postprandial glucose levels in 25 White Dutch males with type 2 diabetes (T2D) on stable metformin therapy. The primary endpoint was the effect of A. soehngenii versus placebo on glucose excursions and variability as determined by continuous glucose monitoring. Secondary endpoints were changes in ambulatory 24-h blood pressure, incretins, circulating metabolites and excursions of plasma short-chain fatty acids (SCFAs) and bile acids upon a standardized meal. Results showed that A. soehngenii supplementation for 14 days significantly improved glycemic variability and mean arterial blood pressure, without notable changes in SCFAs, bile acids, incretin levels, or anthropometric parameters as compared to placebo-treated controls. Although well-tolerated and effective in improving glycemic control in the intervention group, further research in larger and more diverse populations is needed to generalize these findings.
Competing Interests: M.N. and W.M.d.V. are founders and members of the Scientific Advisory Board of Caelus Pharmaceuticals in the Netherlands. W.M.d.V. is the founder and Chief Technology Officer of The Akkermansia Company, Belgium. S.L.H. reports are referred to as co-inventors on pending and issued patents held by the Cleveland Clinic relating to cardiovascular diagnostics and therapeutics, eligible to receive royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland HeartLab, a wholly owned subsidiary of Quest Diagnostics, Procter & Gamble, and Zehna therapeutics. S.L.H. also reports being a paid consultant formerly for Procter & Gamble and currently with Zehna Therapeutics and has received research funds from Procter & Gamble and Zehna Therapeutics.
(© 2024 The Author(s).)